Treatment Guidelines: Osteoporosis

NICE guidelines for the treatment and management of osteoporosis:

NICE TA160
Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women

Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.

https://www.nice.org.uk/guidance/ta160

NICE TA161
Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

Evidence-based recommendations on raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women.

https://www.nice.org.uk/guidance/ta161

NICE TA464
Bisphosphonates for treating osteoporosis

Evidence-based recommendations on bisphosphonates (alendronic acid; ibandronic acid; risedronate sodium; zoledronic acid) for treating osteoporosis in adults.

https://www.nice.org.uk/guidance/ta464

NICE CG146
Osteoporosis: assessing the risk of fragility fracture

This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.

https://www.nice.org.uk/guidance/cg146

NICE TA204
Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.

https://www.nice.org.uk/guidance/ta204

NICE TA279
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures

Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures.

https://www.nice.org.uk/guidance/ta279